5 Key Takeaways

• 1

  Vaccine development is evolving with platform technologies, rapid manufacturing, and global collaboration to enhance preparedness and public trust.

• 2

  Adaptable platforms like mRNA and viral vectors enable rapid response to emerging pathogens while ensuring scalability and manufacturability.

• 3

  The COVID-19 pandemic highlighted supply chain vulnerabilities, prompting CDMOs to adopt dual-sourcing strategies and improve inventory planning.

• 4

  Public trust in vaccines relies on transparent communication and scientific literacy to counter misinformation and enhance confidence in public health.

• 5

  International collaboration in vaccine development is built on trust, fostering partnerships between biotech firms, public institutions, and governments.